Nurix Therapeutics, Inc. SEC filings NRIX

Nurix Therapeutics, Inc. has 561 filings in SEC EDGAR's recent list, going back to May 15, 2012. Its latest annual report, Form ARS, was filed on Mar 27, 2026 for the period ended Nov 30, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 13, 2026, covering the quarter ended Aug 31, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (other events). The company's fiscal year ends on November 30.

Nurix Therapeutics, Inc. SEC filings
Form Description Filed Period
UPLOAD Letter from the SEC Mar 19, 2025 —
CORRESP Letter to the SEC Mar 13, 2025 —
UPLOAD Letter from the SEC Feb 28, 2025 —
EFFECT Filing Apr 6, 2023 —
POSASR Filing Feb 9, 2023 —
POS EX Filing Mar 5, 2021 —
EFFECT Filing Mar 4, 2021 —
CORRESP Letter to the SEC Mar 2, 2021 —
CORRESP Letter to the SEC Mar 2, 2021 —
UPLOAD Letter from the SEC Mar 1, 2021 —
DRS Filing Feb 22, 2021 —
EFFECT Filing Jul 23, 2020 —
CERT Filing Jul 23, 2020 —
CORRESP Letter to the SEC Jul 21, 2020 —
CORRESP Letter to the SEC Jul 21, 2020 —
8-A12B Filing Jul 20, 2020 —
CORRESP Letter to the SEC Jul 10, 2020 —
DRSLTR Filing Jun 10, 2020 —
DRS/A Filing Jun 10, 2020 —
UPLOAD Letter from the SEC Jun 4, 2020 —
DRS Filing May 5, 2020 —
D Filing Mar 26, 2020 —
D Filing Sep 18, 2015 —
D Filing Jan 2, 2014 —
D/A Filing Mar 28, 2013 —
D Filing May 16, 2012 —
D Filing May 15, 2012 —

Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NRIX (Nasdaq)
Fiscal year ends
November 30
Incorporated in
DE
Headquarters
Brisbane, CA
SEC filer status
Large accelerated filer
SEC CIK
1549595
Former names
Nurix, Inc. (until Sep 18, 2015)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.